Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$2.6 million.

  • Cytosorbents' Cash from Operations fell 462.85% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.9 million, marking a year-over-year increase of 4650.92%. This contributed to the annual value of -$14.4 million for FY2024, which is 3337.47% up from last year.
  • Cytosorbents' Cash from Operations amounted to -$2.6 million in Q3 2025, which was down 462.85% from -$1.5 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Cash from Operations ranged from a high of -$1.5 million in Q2 2025 and a low of -$8.1 million during Q1 2022
  • Over the past 5 years, Cytosorbents' median Cash from Operations value was -$4.8 million (recorded in 2024), while the average stood at -$4.5 million.
  • Per our database at Business Quant, Cytosorbents' Cash from Operations tumbled by 41914.99% in 2021 and then skyrocketed by 6850.29% in 2025.
  • Over the past 5 years, Cytosorbents' Cash from Operations (Quarter) stood at -$5.5 million in 2021, then rose by 2.75% to -$5.3 million in 2022, then fell by 19.98% to -$6.4 million in 2023, then soared by 63.47% to -$2.3 million in 2024, then fell by 10.09% to -$2.6 million in 2025.
  • Its Cash from Operations stands at -$2.6 million for Q3 2025, versus -$1.5 million for Q2 2025 and -$3.5 million for Q1 2025.